Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms
Authors:
- Pernille HolmagerPHPernille Holmager
- Seppo W. LangerSLSeppo W. Langer
- Andreas KjaerAndreas Kjaer
- Lene RingholmLRLene Ringholm
- Rajendra Singh GarbyalRajendra Singh Garbyal
- Hans-Christian PommergaardHPHans-Christian Pommergaard
- Carsten Palnæs HansenCHCarsten Palnæs Hansen
- Birgitte FederspielBFBirgitte Federspiel
- Mikkel AndreassenMAMikkel Andreassen
- Ulrich KniggeUlrich Knigge
- 1 April 2022
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 23 (6) , 806-817
Abstract
Opinion statement In the 2019 WHO guidelines, the classification of gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has changed from one being based on Ki-67 proliferation index alone to one that also includes tumor differentiation. Consequently, GEP NENs are now classified as well-differentiated neuroendocrine tumor (NET), NET G1 (Ki-67 20%), and poorly differentiated neuroendocrine carcinoma (NEC) (Ki-67 >20%). It has been suggested that NET G3 should be treated as NET G2 with respect to surgery, while surgical management of NEC should be expanded from local disease to also include patients with advanced disease where curative surgery is possible. High grade mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) have a neuroendocrine and a non-neuroendocrine component mostly with a poor prognosis. All studies evaluating the effect of surgery in NEC and MiNEN are observational and hold a risk of selection bias, which may overestimate the beneficial effect of surgery. Further, only a few studies on the effect of surgery in MiNEN exist. This review aims to summarize the data on the outcome of surgery in patients with GEP NET G3, GEP NEC and high grade MiNEN. The current evidence suggests that patients with NEN G3 and localized disease and NEN G3 patients with metastatic disease where curative surgery can be achieved may benefit from surgery. In patients with MiNEN, it is currently not possible to evaluate on the potential beneficial effect of surgery due to the low number of studies.Keywords
Funding Information
- Harboefonden
- Dagmar Marshalls Fond
This publication has 44 references indexed in Scilit:
- Poorly Differentiated Neuroendocrine Carcinomas of the PancreasAmerican Journal of Surgical Pathology, 2014
- Clinicopathologic Study of 62 Acinar Cell Carcinomas of the PancreasAmerican Journal of Surgical Pathology, 2012
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- Colorectal Poorly Differentiated Neuroendocrine Carcinomas and Mixed Adenoneuroendocrine CarcinomasAmerican Journal of Surgical Pathology, 2012
- Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organsVirchows Archiv, 2012
- Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An UpdateCancers, 2012
- Clinical features of 20 patients with curatively resected biliary neuroendocrine tumoursDigestive and Liver Disease, 2011
- The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine CarcinomasPancreas, 2010
- Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumoursEndocrine-Related Cancer, 2008
- Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the EsophagusAmerican Journal of Surgical Pathology, 2008